
    
      This is a phase II, randomized, controlled, two-center pilot study designed to assess the
      safety and efficacy of MEBO in the treatment of subjects with DFUs. Subjects meeting entry
      criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either
      MEBO or SOC.
    
  